Home > Insider Trading > Filing (0001764013-24-000010)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1764013	Immunovant Inc.	IMVT	Biological Products, (No Disgnostic Substances) (2836)	832771572

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1883766	Renee Eva Barnett	C/O Immunovant, Inc. 320 W 37Th Street, 6Th Floor New York NY 10018	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-01-11	2,681	$41.64	324,184	No	4	S	Direct
Common Stock	Disposition	2024-01-11	834	$42.43	323,350	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.06 - $42.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.17 - $42.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.